NDC 63323-325 Acyclovir

Acyclovir Sodium

NDC Product Code 63323-325

NDC CODE: 63323-325

Proprietary Name: Acyclovir What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Acyclovir Sodium What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • This medication is used in certain people to treat outbreaks of herpes simplex infection of the skin (e.g., genitals), mucous membrane areas (e.g., mouth, nose), or brain. It is also used in certain people to treat shingles infection. The viruses that cause these infections live in the body quietly until an outbreak occurs. Acyclovir does not cure these infections, but can speed healing of the sores, decrease pain/itching/formation of new sores, and lower the risk of other problems from the virus (e.g., infection spreading to other parts of the body/organs, persistent pain after sores heal).
  • This medication is used in certain people to treat outbreaks of herpes simplex infection of the skin (e.g., genitals), mucous membrane areas (e.g., mouth, nose), or brain. It is also used in certain people to treat shingles infection. The viruses that cause these infections live in the body quietly until an outbreak occurs. Acyclovir does not cure these infections, but can speed healing of the sores, decrease pain/itching/formation of new sores, and lower the risk of other problems from the virus (e.g., infection spreading to other parts of the body/organs, persistent pain after sores heal).

NDC Code Structure

NDC 63323-325-10

Package Description: 10 VIAL, SINGLE-DOSE in 1 TRAY > 10 mL in 1 VIAL, SINGLE-DOSE

NDC 63323-325-14

Package Description: 10 VIAL, SINGLE-DOSE in 1 TRAY > 10 mL in 1 VIAL, SINGLE-DOSE

NDC 63323-325-20

Package Description: 10 VIAL, SINGLE-DOSE in 1 TRAY > 20 mL in 1 VIAL, SINGLE-DOSE

NDC 63323-325-24

Package Description: 10 VIAL, SINGLE-DOSE in 1 TRAY > 20 mL in 1 VIAL, SINGLE-DOSE

NDC Product Information

Acyclovir with NDC 63323-325 is a a human prescription drug product labeled by Fresenius Kabi Usa, Llc. The generic name of Acyclovir is acyclovir sodium. The product's dosage form is injection, solution and is administered via intravenous form.

Labeler Name: Fresenius Kabi Usa, Llc

Dosage Form: Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Acyclovir Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • ACYCLOVIR SODIUM 50 mg/mL
  • ACYCLOVIR SODIUM 50 mg/mL

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intravenous - Administration within or into a vein or veins.
  • Intravenous - Administration within or into a vein or veins.
  • Intravenous - Administration within or into a vein or veins.
  • Intravenous - Administration within or into a vein or veins.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • DNA Polymerase Inhibitors - [MoA] (Mechanism of Action)
  • Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
  • Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
  • Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
  • Nucleoside Analog - [EXT]
  • DNA Polymerase Inhibitors - [MoA] (Mechanism of Action)
  • Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
  • Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
  • Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
  • Nucleoside Analog - [EXT]

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Fresenius Kabi Usa, Llc
Labeler Code: 63323
FDA Application Number: ANDA074930 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 10-17-2000 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2020 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Information for Patients

Acyclovir Injection

Acyclovir Injection is pronounced as (ay sye' kloe ver)

Why is acyclovir injection medication prescribed?
Acyclovir injection is used to treat first-time or repeat outbreaks of herpes simplex (a herpes virus infection of the skin and mucus membranes) and to treat herpes zoste...
[Read More]

* Please review the disclaimer below.

Acyclovir Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Description

Acyclovir Sodium Injection is a synthetic nucleoside analog, active against herpes viruses.  It is a sterile, aqueous solution for intravenous infusion, containing 50 mg acyclovir per mL in Water for Injection, USP.  The concentration is equivalent to 54.9 mg of acyclovir sodium per mL in Water for Injection, USP.  The sodium content is approximately 5.1 mg/mL.  The pH range of the solution is 10.85 to 11.50.  Further dilution of Acyclovir Sodium Injection in an appropriate intravenous solution must be performed before infusion (see


DOSAGE AND ADMINISTRATION, Administration).


The chemical name of acyclovir sodium is 9-[(2-Hydroxyethoxy)methyl] guanine, and has the following structural formula:  


 Acyclovir sodium is a white, crystalline powder with the molecular formula C


8H


10N


5NaO


3 and a molecular weight of 247.19.  The maximum solubility in water at 25°C exceeds 100 mg/mL.  At physiologic pH, acyclovir sodium exists as the unionized form with a molecular weight of 225 and a maximum solubility in water at 37°C of 2.5 mg/mL.  The pka’s of acyclovir are 2.27 and 9.25.

Mechanism Of Antiviral Action

Acyclovir is a synthetic purine nucleoside analogue with


in vitro and


in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2) and varicella-zoster virus (VZV).


The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV.  This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue.  The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. 


In vitro, acyclovir triphosphate stops replication of herpes viral DNA.  This is accomplished in three ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase.  The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the viral TK.

Antiviral Activities

The quantitative relationship between the


in vitro susceptibility of herpes viruses to antivirals and the clinical response to therapy has not been established in humans, and virus sensitivity testing has not been standardized.  Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (IC


50), vary greatly depending upon a number of factors.  Using plaque-reduction assays, the IC


50 against herpes simplex virus isolates ranges from 0.02 to 13.5 mcg/mL for HSV-1 and from 0.01 to 9.9 mcg/mL for HSV-2.  The IC


50 for acyclovir against most laboratory strains and clinical isolates of VZV ranges from 0.12 to 10.8 mcg/mL.  Acyclovir also demonstrates activity against the Oka vaccine strain of VZV with a mean IC


50 of 1.35 mcg/mL.

Drug Resistance

Resistance of HSV and VZV to acyclovir can result from qualitative or quantitative changes in the viral TK and/or DNA polymerase.  Clinical isolates of HSV and VZV with reduced susceptibility to acyclovir have been recovered from immunocompromised patients, especially with advanced HIV infection.  While most of the acyclovir-resistant mutants isolated thus far from such patients have been found to be TK-deficient mutants, other mutants involving the viral TK gene (TK partial and TK altered) and DNA polymerase have been isolated.  TK-negative mutants may cause severe disease in infants and immunocompromised adults.  The possibility of viral resistance to acyclovir should be considered in patients who show poor clinical response during therapy.

Pharmacokinetics

The pharmacokinetics of acyclovir after intravenous administration have been evaluated in adult patients with normal renal function during Phase 1/2 studies after single doses ranging from 0.5 to 15 mg/kg and after multiple doses ranging from 2.5 to 15 mg/kg every 8 hours.  Proportionality between dose and plasma levels is seen after single doses or at steady-state after multiple dosing.  Average steady-state peak and trough concentrations from 1-hour infusions administered every 8 hours are given in Table 1.Table 1: Acyclovir Peak and Trough Concentrations



                          at Steady-State


Dosage RegimenC


SSmaxC


SStrough5 mg/kg q 8 h(n=8)9.8 mcg/mLrange: 5.5 to 13.80.7 mcg/mLrange: 0.2 to 110 mg/kg q 8 h(n=7)22.9 mcg/mLrange: 14.1 to 44.11.9 mcg/mLrange: 0.5 to 2.9Concentrations achieved in the cerebrospinal fluid are approximately 50% of plasma values.  Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.Renal excretion of unchanged drug is the major route of acyclovir elimination accounting for 62% to 91% of the dose.  The only major urinary metabolite detected is 9-carboxymethoxymethylguanine accounting for up to 14.1% of the dose in patients with normal renal function.The half-life and total body clearance of acyclovir are dependent on renal function as shown in Table 2.       Table 2: Acyclovir Half-life and Total Body Clearance Creatinine Clearance(mL/min/1.73 m


2)


         Total Body ClearanceHalf-Life(hr) (mL/min/1.73 m


2)


 (mL/min/kg)>8050 to 8015 to 500 (Anuric)2.533.519.5327248190295.13.93.40.5

Special Populations

Adults with Impaired Renal FunctionAcyclovir was administered at a dose of 2.5 mg/kg to 6 adult patients with severe renal failure.  The peak and trough plasma levels during the 47 hours preceding hemodialysis were 8.5 mcg/mL and 0.7 mcg/mL, respectively.Consult


DOSAGE AND ADMINISTRATION section for recommended adjustments in dosing based upon creatinine clearance.


 PediatricsAcyclovir pharmacokinetics were determined in 16 pediatric patients with normal renal function ranging in age from 3 months to 16 years at doses of approximately 10 mg/kg and 20 mg/kg every 8 hours (Table 3).  Concentrations achieved at these regimens are similar to those in adults receiving 5 mg/kg and 10 mg/kg every 8 hours, respectively (Table 1).  Acyclovir pharmacokinetics were determined in 12 patients ranging in age from birth to 3 months at doses of 5 mg/kg, 10 mg/kg, and 15 mg/kg every 8 hours (Table 3).         Table 3: Acyclovir Pharmacokinetics in Pediatric Patients (Mean ± SD) ParameterBirth to 3 Months of Age(n=12)3 Months to 12 Years of Age (n=16)CL (mL/min/kg)4.46 ± 1.618.44 ± 2.92VDSS (L/kg)1.08 ± 0.351.01 ± 0.28Elimination half-life(hours) 3.8 ± 1.19 2.36 ± 0.97GeriatricsAcyclovir plasma concentrations are higher in geriatric patients compared to younger adults, in part due to age-related changes in renal function.  Dosage reduction may be required in geriatric patients with underlying renal impairment (see


PRECAUTIONS, Geriatric Use).

Drug Interactions

Coadministration of probenecid with acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve.  Urinary excretion and renal clearance were correspondingly reduced.

See


CLINICAL PHARMACOLOGY, Pharmacokinetics.

Herpes Simplex Infections In Immunocompromised Patients

A multicenter trial of acyclovir at a dose of 250 mg/m


2 every 8 hours (750 mg/m


2/day) for 7 days was conducted in 98 immunocompromised patients (73 adults and 25 children) with orofacial, esophageal, genital and other localized infections (52 treated with acyclovir and 46 with placebo).  Acyclovir decreased virus excretion, reduced pain, and promoted healing of lesions.

Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients.

Initial Episodes Of Herpes Genitalis

In placebo-controlled trials, 58 patients with initial genital herpes were treated with intravenous acyclovir 5 mg/kg or placebo (27 patients treated with acyclovir and 31 treated with placebo) every 8 hours for 5 days.  Acyclovir decreased the duration of viral excretion, new lesion formation, and duration of vesicles, and promoted healing of lesions.

Acyclovir Sodium Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immuno-competent patients.

Herpes Simplex Encephalitis

Sixty-two patients ages 6 months to 79 years with brain biopsy-proven herpes simplex encephalitis were randomized to receive either acyclovir (10 mg/kg every 8 hours) or vidarabine (15 mg/kg/day) for 10 days (28 were treated with acyclovir and 34 with vidarabine).  Overall mortality at 12 months for patients treated with acyclovir was 25% compared to 59% for patients treated with vidarabine.  The proportion of patients treated with acyclovir functioning normally or with only mild sequelae (e.g., decreased attention span) was 32% compared to 12% of patients treated with vidarabine.Patients less than 30 years of age and those who had the least severe neurologic involvement at time of entry into study had the best outcome with treatment with acyclovir.  An additional controlled study performed in Europe demonstrated similar findings.

Acyclovir Sodium Injection is indicated for the treatment of herpes simplex encephalitis.

Neonatal Herpes Simplex Virus Infection

Two hundred and two infants with neonatal herpes simplex infections were randomized to receive either acyclovir 10 mg/kg every 8 hours (n=107) or vidarabine 30 mg/kg/day (n=95) for 10 days.  Outcomes are presented in Table 4.                Table 4: Mortality at 1 Year HSV Disease ClassificationTreatment GroupAcyclovir(n=107)Vidarabine(n=95)SEM


* (n=85)


0/540/31CNS


† (n=71)


5/355/36DISS


‡ (n=46)


11/1814/28* SEM refers to localized infection with disease limited to skin, eye, and/or mouth.† CNS refers to infection of the central nervous system with compatible neurologic and CSF findings.‡ DISS refers to visceral organ involvement such as hepatitis or pneumonitis with or without CNS involvement. Rates of neurologic sequelae at 1 year were comparable between the treatment groups.

Acyclovir Sodium Injection is indicated for the treatment of neonatal herpes infections.

Varicella-Zoster Infetions In Immunocompromised Patients

A multicenter trial of acyclovir at a dose of 500 mg/m


2 every 8 hours for 7 days was conducted in immunocompromised patients with zoster infections (shingles).  Ninety-four (94) patients were evaluated (52 patients were treated with acyclovir and 42 with placebo).  Acyclovir was superior to placebo as measured by reductions in cutaneous dissemination and visceral dissemination.

Varicella-Zoster Infections In Immunocompromised Patients

Acyclovir Sodium Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients.

Contraindications

Acyclovir Sodium Injection is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

Warnings

Acyclovir Sodium Injection is intended for intravenous infusion only, and should not be administered topically, intramuscularly, orally, subcutaneously, or in the eye.  Intravenous infusions must be given over a period of at least 1 hour to reduce the risk of renal tubular damage (see


PRECAUTIONS and


DOSAGE AND ADMINISTRATION).


Renal failure, in some cases resulting in death, has been observed with acyclovir therapy (see


ADVERSE REACTIONS, Observed During Clinical Practice and


OVERDOSAGE).  Thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome (TTP/HUS), which has resulted in death, has occurred in immunocompromised patients receiving acyclovir therapy.

General

Precipitation of acyclovir crystals in renal tubules can occur if the maximum solubility of free acyclovir (2.5 mg/mL at 37°C in water) is exceeded or if the drug is administered by bolus injection.  Ensuing renal tubular damage can produce acute renal failure.Abnormal renal function (decreased creatinine clearance) can occur as a result of acyclovir administration and depends on the state of the patient’s hydration, other treatments, and the rate of drug administration.  Concomitant use of other nephrotoxic drugs, pre-existing renal disease, and dehydration make further renal impairment with acyclovir more likely.Administration of acyclovir by intravenous infusion must be accompanied by adequate hydration.When dosage adjustments are required, they should be based on estimated creatinine clearance (see


DOSAGE AND ADMINISTRATION).


Approximately 1% of patients receiving intravenous acyclovir have manifested encephalopathic changes characterized by either lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Acyclovir should be used with caution in those patients who have underlying neurologic abnormalities and those with serious renal, hepatic, or electrolyte abnormalities, or significant hypoxia.

Carcinogenesis, Mutagenesis, Impairment Of Fertility

The data presented below include references to peak steady-state plasma acyclovir concentrations observed in humans treated with 30 mg/kg/day (10 mg/kg every 8 hours, dosing appropriate for treatment of herpes zoster or herpes encephalitis), or 15 mg/kg/day (5 mg/kg every 8 hours, dosing appropriate for treatment of primary genital herpes or herpes simplex infections in immunocompromised patients).  Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir at the higher and lower dosing schedules (see


CLINICAL PHARMACOLOGY, Pharmacokinetics).


Acyclovir was tested in lifetime bioassays in rats and mice at single daily doses of up to 450 mg/kg administered by gavage.  There was no statistically significant difference in the incidence of tumors between treated and control animals, nor did acyclovir shorten the latency of tumors.  At 450 mg/kg/day, plasma concentrations in both the mouse and rat bioassay were lower than concentrations in humans.Acyclovir was tested in 16


in vitro and


in vivo genetic toxicity assays.  Acyclovir was positive in 5 of the assays.


Acyclovir did not impair fertility or reproduction in mice (450 mg/kg/day, PO) or in rats (25 mg/kg/day, SC).  In the mouse study, plasma levels were the same as human levels, while in the rat study, they were 1 to 2 times human levels.  At higher doses (50 mg/kg/day, SC) in rats and rabbits (1 to 2 and 1 to 3 times human levels, respectively) implantation efficacy, but not litter size, was decreased.  In a rat peri- and post-natal study at 50 mg/kg/day, SC, there was a statistically significant decrease in group mean numbers of corpora lutea, total implantation sites, and live fetuses.No testicular abnormalities were seen in dogs given 50 mg/kg/day, IV for 1 month (1 to 3 times human levels) or in dogs given 60 mg/kg/day orally for 1 year (the same as human levels).  Testicular atrophy and aspermatogenesis were observed in rats and dogs at higher dose levels.

Pregnancy

Teratogenic EffectsPregnancy Category B.Acyclovir administered during organogenesis was not teratogenic in the mouse (450 mg/kg/day, PO), rabbit (50 mg/kg/day, SC and IV) or rat (50 mg/kg/day, SC).  These exposures resulted in plasma levels the same as, 4 and 9, and 1 and 2 times, respectively, human levels.There are no adequate and well-controlled studies in pregnant women.  A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999.  There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes.  The occurrence rate of birth defects approximates that found in the general population.  However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses.  Acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Acyclovir concentrations have been documented in breast milk in two women following oral administration of acyclovir and ranged from 0.6 to 4.1 times corresponding plasma levels.  These concentrations would potentially expose the nursing infant to a dose of acyclovir up to 0.3 mg/kg/day.  Acyclovir should be administered to a nursing mother with caution and only when indicated.

Pediatric Use

See


DOSAGE AND ADMINISTRATION.

Geriatric Use

Clinical studies of acyclovir did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.  Other reported clinical experience has identified differences in the severity of CNS adverse events between elderly and younger patients (see


ADVERSE REACTIONS, Observed During Clinical Practice).  In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased renal function, and of concomitant disease or other drug therapy.  This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Adverse Reactions

The adverse reactions listed below have been observed in controlled and uncontrolled clinical trials in approximately 700 patients who received acyclovir at approximately 5 mg/kg (250 mg/m


2) 3 times daily, and approximately 300 patients who received approximately 10 mg/kg (500 mg/m


2) 3 times daily.


The most frequent adverse reactions reported during administration of acyclovir were inflammation or phlebitis at the injection site in approximately 9% of the patients, and transient elevations of serum creatinine or BUN in 5% to 10% (the higher incidence occurred usually following rapid [less than 10 minutes] intravenous infusion).  Nausea and/or vomiting occurred in approximately 7% of the patients (the majority occurring in nonhospitalized patients who received 10 mg/kg).  Itching, rash, or hives occurred in approximately 2% of patients.  Elevation of transaminases occurred in 1% to 2% of patients.The following hematologic abnormalities occurred at a frequency of less than 1%: anemia, neutropenia, thrombocytopenia, thrombocytosis, leukocytosis, and neutrophilia.  In addition, anorexia and hematuria were observed.

Observed During Clinical Practice

In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of Acyclovir Sodium Injection in clinical practice.  Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.  These events have been chosen for inclusion due to either their seriousness, frequency of reporting, potential causal connection to acyclovir, or a combination of these factors.General:  Anaphylaxis, angioedema, fatigue, fever, headache, pain, peripheral edema.


Digestive:  Abdominal pain, diarrhea, gastrointestinal distress, nausea.


Cardiovascular:  Hypotension.


Hematologic and Lymphatic:  Disseminated intravascular coagulation, hemolysis,leukocytoclastic vasculitis, leukopenia, lymphadenopathy.


Hepatobiliary Tract and Pancreas:  Elevated liver function tests, hepatitis, hyperbilirubinemia,jaundice.


Musculoskeletal:  Myalgia.


Nervous:  Aggressive behavior, agitation, ataxia, coma, confusion, delirium, dizziness, dysarthria, encephalopathy, hallucinations, obtundation, paresthesia, psychosis, seizure, somnolence, tremor.  These symptoms may be marked, particularly in older adults (see


PRECAUTIONS).


Skin:  Alopecia, erythema multiforme, photosensitive rash, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria.  Severe local inflammatory reactions, including tissue necrosis, have occurred following infusion of acyclovir into extravascular tissues.


Special Senses:  Visual abnormalities.


Urogenital:  Renal failure, elevated blood urea nitrogen, elevated creatinine (see


WARNINGS).

Overdosage

Overdoses involving ingestions of up to 20 g have been reported.  Adverse events that have been reported in association with overdosage include agitation, coma, seizures, and lethargy.  Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid.  Overdosage has been reported following bolus injections or inappropriately high doses, and in patients whose fluid and electrolyte balance were not properly monitored.  This has resulted in elevated BUN and serum creatinine, and subsequent renal failure.  In the event of acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored (see


DOSAGE AND ADMINISTRATION).

Dosage And Administration

CAUTION - RAPID OR BOLUS INTRAVENOUS INJECTION MUST BE AVOIDED (see


WARNINGS and


PRECAUTIONS).


INTRAMUSCULAR OR SUBCUTANEOUS INJECTION MUST BE AVOIDED (see


WARNINGS).


Therapy should be initiated as early as possible following onset of signs and symptoms of herpes infections. 


A maximum dose equivalent to 20 mg/kg every 8 hours should not be exceeded for any patient.

Dosage

HERPES SIMPLEX INFECTIONSMUCOSAL AND CUTANEOUS HERPES SIMPLEX (HSV-1 and HSV-2)INFECTIONS IN IMMUNOCOMPROMISED PATIENTS:Adults and Adolescents (12 years of age and older):5 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days. Pediatrics (Under 12 years of age):10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days. SEVERE INITIAL CLINICAL EPISODES OF HERPES GENITALIS:Adults and Adolescents (12 years of age and older):5 mg/kg infused at a constant rate over 1 hour, every 8 hours for 5 days. HERPES SIMPLEX ENCEPHALITIS:Adults and Adolescents (12 years of age and older): 


10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days. Pediatrics (3 months to 12 years of age):20 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days. Neonatal Herpes Simplex Virus Infections (Birth to 3 months):10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days.  In neonatal herpes simplex infections, doses of 15 mg/kg or 20 mg/kg (infused at a constant rate over 1 hour every 8 hours) have been used; the safety and efficacy of these doses are not known.VARICELLA-ZOSTER INFECTIONSZOSTER IN IMMUNO­COMPROMISED PATIENTS:Adults and Adolescents (12 years of age and older: 


10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days. Pediatrics (Under 12 years of age):20 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days.

Obese Patients

Obese patients should be dosed at the recommended adult dose using Ideal Body Weight.PATIENTS WITH ACUTE OR CHRONIC RENAL IMPAIRMENT: Refer to


DOSAGE AND ADMINISTRATION section for recommended doses, and adjust the dosing interval as indicated in Table 5.


Table 5: Dosage Adjustments for Patients with Renal ImpairmentCreatinine Clearance(mL/min/1.73 m


2)


Percent of Recommended DoseDosing Interval (hours)>5025 to 5010 to 250 to 10100%100%100%50%8122424

Hemodialysis

For patients who require dialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours.  This results in a 60% decrease in plasma concentrations following a six-hour dialysis period.  Therefore, the patient’s dosing schedule should be adjusted so that an additional dose is administered after each dialysis.

Peritoneal Dialysis

No supplemental dose appears to be necessary after adjustment of the dosing interval.

Administration

The calculated dose should be further diluted in an appropriate intravenous solution at a volume selected for administration during each 1 hour infusion.  Infusion concentrations of approximately 7 mg/mL or lower are recommended.  In clinical studies, the average 70 kg adult received between 60 and 150 mL of fluid per dose.  Higher concentrations (e.g., 10 mg/mL) may produce phlebitis or inflammation at the injection site upon inadvertent extravasation.  Standard, commercially available electrolyte and glucose solutions are suitable for intravenous administration; biologic or colloidal fluids (e.g., blood products, protein solutions, etc.) are not recommended.Once diluted for administration, each dose should be used within 24 hours.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

How Supplied

Acyclovir Sodium Injection is available as:ProductNo.NDC No.Strength 30251063323-325-10 500 mg per 10 mL(50 mg per mL)Acyclovir Sodium Injection equivalent to acyclovir, in a 10 mL plastic vial, in packages of 10.30252063323-325-201,000 mg per 20 mL(50 mg per mL)Acyclovir Sodium Injection equivalent to acyclovir, in a 20 mL plastic vial, in packages of 10.Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Discard unused portion.This container closure is not made with natural rubber latex.

* Please review the disclaimer below.